The outcomes of surgical treatment of benign prostatic hyperplasia (BPH) has been verified as it causes few complications. However, if complications develop, they will have significant impacts on patients’ quality of life. Therefore, in order to provide individualized treatments, patients’ general condition, expectations of treatment, clinical symptoms, prostate volume, advantages and disadvantages of different operative methods and operators’ mastery of operative methods should be considered to reduce the incidence of postoperative complications such as stress incontinence, urethral stricture and bladder neck contracture. This article discusses the choices of surgical interventions of BPH from the perspective of surgical safety and reduction of complications so as to improve the satisfaction of patients.

Benign prostatic hyperplasia (BPH) may lead to benign prostatic obstruction (BPO), which may result in bladder dysfunction. Based on the urodynamic analysis of bladder function of 793 BPO patients, bladder function could be classified into 3 stages and 6 types. Detrusor overactivity with impaired contractility (DHIC) is the transitional period of bladder function from compensation to decompensation. The indications of surgical therapy of bladder outlet obstruction (BOO) in different guidelines do not consider the bladder function. This paper emphasizes the importance of bladder function in the surgical choices for BOO, in order to select targeted and individualized surgical methods, and discusses the choice of surgical treatment for BPO from the perspective of bladder function.

Objective:To evaluate the efficacy of cyclophosphamide(CYP)at different doses in repli-cating the symptoms of interstitial cystitis/bladder pain syndrome(IC/BPS)in an animal model,thereby providing an experimental basis for understanding the pathophysiology of IC/BPS and assessing treatment strategies.Methods:Twenty-eight female Sprague-Dawley rats aged seven weeks were divided into four groups:Group a(25 mg/kg CYP),group b(75 mg/kg CYP),group c(125 mg/kg CYP),and group d(a control group).The rats were injected intraperitoneally with either CYP or saline solution.Evalua-tions included urine spot tests,von Frey filament pain threshold tests,urodynamic examinations,and his-tological assessments.Results:The study found that the 25 mg/kg CYP dosage significantly outperformed higher doses in simulating bladder dysfunction and inflammatory responses while minimizing the impact on the rats'physiological functions.Specifically,urine spot area,group a showed a significant reduction in urine spot area compared with the control group(P＜0.05),while groups b and c did not show signifi-cant differences.Pain threshold:The von Frey filament test indicated increased visceral pain in group a,aligning closely with IC/BPS patient symptoms,without a significant increase in urination frequency.Urodynamic assessments:Group a exhibited decreased bladder compliance and reduced maximum bladder capacity(P＜0.05),with no significant differences in baseline bladder pressure and maximum detrusor pressure across all groups.Histological analysis:Hematoxylin-eosin(HE)staining revealed that bladder tissue in group a had moderate inflammatory reactions,whereas groups b and c showed severe inflamma-tion and tissue damage,correlating with the higher doses of CYP.Furthermore,the urine spot tests and von frey filament tests provided quantitative data supporting the model's reliability,urine spot count,group a had an average urine spot count of(15±3)spots,significantly higher than the control group's(5±2)spots(P＜0.01).Nociceptive score:Group a nociceptive score increased to 0.5±0.1,indica-ting heightened pain sensitivity compared with the control group 0.10±0.05(P＜0.01).Conclusion:The 25 mg/kg CYP demonstrated significant advantages in simulating the key features of non-ulcerative IC/BPS,summarizing the main aspects of the human condition,including persistent visceral pain and mild inflammatory reactions in bladder tissue.These findings offer substantial experimental support for drug development and treatment research in IC/BPS and provide new insights into the complex patho-physiology of the disease.

【Objective】 To explore the clinical features and treatment outcomes of female urethral carcinoma so as to improve the awareness and prognosis of this rare malignant disease. 【Methods】 Clinical data of 8 cases of female urethral carcinoma treated during Jan. 2012 to Dec.2022 at the Department of Urology of Peking University People’s Hospital were retrospectively analyzed. The patients underwent urodynamic tests, cystourethroscopy and pathological biopsy to confirm the diagnosis. Traditional radical surgery was performed in 5 cases, and radical surgery for lower urethral cancer with bladder preservation was performed in 3 cases. 【Results】 The patients aged 36 to 68 years, with a mean of 53.75 years. Urinary obstruction, lower urinary tract symptoms and urethral masses were common manifestations. Urodynamic tests indicated bladder outlet obstruction. After surgical treatment, radical surgery for lower urethral cancer with bladder preservation showed advantages over traditional radical surgery in terms of intraoperative bleeding, operation time and postoperative hospital stay. 【Conclusion】 Female primary urethral carcinoma is rare but invasive. Early diagnosis and radical surgery are crucial for improving the prognosis. Radical surgery for lower urethral cancer with bladder preservation has better treatment outcomes and postoperative quality of life compared to traditional radical surgery. For such patients, symptoms should be closely monitored and timely diagnosis and treatment should be performed.